Mini Oral Session

Mini Oral Session 1

· Room: 503 December 4th 07:30-08:30 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
07:30-07:37	ASGO20260451	Human omental decellularized extracellular matrix enhances ovarian cancer aggressiveness and models patient-specific chemotherapy response in three-dimensional culture	Nan Zhang	China mainland
07:37-07:44	ASGO20260358	A contact-inflammatory tumor-associated macrophage state tracks lymphocyte exhaustion across ovarian cancer niches	Yi Xu	China mainland
07:44-07:51	ASGO20260382	TMC6 Shapes an Immune-active Tumor Microenvironment and Enhances CD8D T-cell-mediated Antitumor Immunity in Ovarian Cancer	Bo Yin	China mainland
07:51-07:58	ASGO20260008	Mg²D-Functionalized EpCAM-Targeted Nanocomplex for Safe and Efficient Tumor-Specific Therapy and Immune Activation in Cervical and Ovarian Cancer	Junfen Xu	China mainland
07:58-08:05	ASGO20260239	Exploration of Vγ9Vδ2 T Cell Death Modes and Related Sensitization Strategies in the Tumor Microenvironment of Cervical Cancer	Jian Liu	China mainland
08:05-08:12	ASGO20260471	SPC25 Drives Cytokinesis and Proliferation in Ovarian Cancer through EPS15-Mediated Cholesterol Endocytic Reprogramming	Shirong Zou	China mainland
08:12-08:19	ASGO20260368	TP53-mutant fallopian tube epithelial cells promote early immune evolutionary selection through VTCN1-positive extracellular vesicles during high-grade serous ovarian carcinogenesis	Qiulei Wu	China mainland
08:19-08:26	ASGO20260028	Cancer-Associated Fibroblast-Derived Epiphycan (EPYC) in Ascites Predicts Suboptimal Cytoreduction and Identifies Omental Metastasis in Ovarian Cancer	Deng Lu	China mainland

Mini Oral Session 2

· Room: 503 December 4th 08:30-09:30 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
08:30-08:37	ASGO20260138	Serum proteomics identifies a functionally validated four-protein panel for endometrial cancer diagnosis	Wanshan Liu	China mainland
08:37-08:44	ASGO20260147	Tertiary lymphoid structures improved survival outcomes in patients with endometrial cancer: a single team experience	Qin Meng	China mainland
08:44-08:51	ASGO20260131	Multi-omic dissection of NSMP endometrial cancer links prognostic heterogeneity to routine-pathology risk stratification and Wnt-associated vulnerability	Xiaodie Liu	China mainland
08:51-08:58	ASGO20260351	Prognostic Evaluation and Risk Stratification of the 2023 FIGO Staging System for Endometrial Cancer Incorporating Molecular Classification	Zhengmao Zhang	China mainland
08:58-09:05	ASGO20260636	Prognostic Significance of Peritoneal Cytology Across Molecular Subtypes of Endometrial Cancer	YuanPei Wang	China mainland
09:05-09:12	ASGO20260464	Three-gene methylation(CELF4, ZSCAN12, and BMP3) analysis outperforms cytology in detecting endometrial cancer: a prospective cohort study using endometrial brush samples	Chongyang Du	China mainland
09:12-09:19	ASGO20260130	Routine Clinical and Serological Variables Reveal Reproducible Phenotypic Heterogeneity in Early-Stage NSMP Endometrial Cancer: A Multicenter Exploratory Study	Xiaodie Liu	China mainland
09:19-09:26	ASGO20260655	Whole-Slide Digital Quantification Reveals Primary–Metastatic Heterogeneity of Folate Receptor Alpha Expression in Uterine Serous Carcinoma	Yusuke Matoba	Japan

Mini Oral Session 3

· Room: 503 December 4th 09:35-10:35 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
09:35-09:42	ASGO20260510	A tumor-resident bacterium, Comamonas testosteroni, promotes cervical cancer progression through estrogen metabolic reprogramming	Yueheng Liu	China mainland
09:42-09:49	ASGO20260031	HPV16/18 Integration Drives Sp1-Mediated Epigenomic Reprogramming to Promote Immune Evasion in Cervical Cancer	Canhui Cao	China mainland
09:49-09:56	ASGO20260042	Prospective Evaluation of Ultrasensitive ddPCR and NGS for Circulating Tumor HPV DNA in Cervical Cancer	Liu Yi	China mainland
09:56-10:03	ASGO20260641	The identification of plasma exosomal protein biomarkers for cervical cancer with lymph node metastasis	Mengzhen Zhang	China mainland
10:03-10:10	ASGO20260231	Spatial Niche Characteristics and Intercellular Interactions in Lymph Node Metastasis of Cervical Cancer: A Multi-Omics Study	Yunyun Liu/ Chunxian Huang	China mainland
10:10-10:17	ASGO20260695	Real-World Treatment Discontinuation Patterns and Outcomes of Paclitaxel-Cisplatin-Bevacizumab in Advanced or Recurrent Cervical Cancer	Aeran Seol	Korea
10:17-10:24	ASGO20260308	Clinical Feasibility and Prognostic Determinants of Immune Checkpoint Inhibitor Rechallenge in Metastatic Cervical Cancer: A Multicenter Real-World Study	Lihua Chen	China mainland
10:24-10:31	ASGO20260694	Real-World Clinical Outcomes and Safety of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer	Masami Takemura	Japan

Mini Oral Session 4

· Room: 503 December 4th 10:40-11:40 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
10:40-10:47	ASGO20260240	Mechanistic Investigation of Tumor-Derived Osteopontin and Fibroblast C-X-C Motif Chemokine Ligand 12 Signaling Through Integrin Pathways in Choriocarcinoma Lung Metastasis, Immune Exclusion, and Checkpoint Response	Haoyu Wang	China mainland
10:47-10:54	ASGO20260590	Prognostic value of systematic lymph node dissection versus sentinel lymph node biopsy in lymph node-negative vulvar melanoma: a multicenter cohort study	Penglin Liu	China mainland
10:54-11:01	ASGO20260421	Prognostic Risk Stratification for Postoperative Neuroendocrine Cervical Carcinoma: A Multicenter, Retrospective Cohort Study	Xuesong Xiang	China mainland
11:01-11:08	ASGO20260124	Real-world treatment patterns and postoperative risk stratification in gastric-type endocervical adenocarcinoma: a Chinese multicenter cohort study	Xuemin Jia	China mainland
11:08-11:15	ASGO20260424	Oncologic Safety of Ovarian Preservation in Neuroendocrine Cervical Carcinoma: A Multicenter, Retrospective Cohort Study	Xuesong Xiang	China mainland
11:15-11:22	ASGO20260708	Predictors of resistance to first-line single-agent chemotherapy in low-risk gestational trophoblastic neoplasia: a systematic review and meta-analysis	Julianti Kelli	Indonesia
11:22-11:29	ASGO20260687	Paclitaxel plus platinum versus standard multidrug chemotherapy as first-line treatment for high-risk gestational trophoblastic neoplasia: a multicenter randomized noninferiority trial	Tao Shen	China mainland
11:29-11:36	ASGO20260601	Mismatch repair deficiency and clinical outcomes in primary endometrial neuroendocrine carcinoma: a Japanese multicenter retrospective study	Hiranuma Kengo	Japan
11:36-11:43	ASGO20260611	Molecular Characteristics and Prognostic Analysis of Small Cell Neuroendocrine Carcinoma of the Cervix Based on Proteomics	Lingcong Yang	China mainland

Mini Oral Session 5

· Room: 503 December 4th 13:00-14:00 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
13:00-13:07	ASGO20260110	Moderately Hypofractionated Online Adaptive Chemoradiotherapy for Cervical Cancer: Prospective Clinical Outcomes and Comparative Analysis With Conventional Fractionation	Zeng Zheng	China mainland
13:07-13:14	ASGO20260249	CYP4A22-AS1 Controls YBX1 Nuclear Accumulation to Promote Metabolic Adaptation and Radioresistance in Cervical Adenocarcinoma	Mingyi Zhou	China mainland
13:14-13:21	ASGO20260092	CT-Based Brachytherapy With MRI Correlation in Cervical Cancer: Validation of the ≥85 Gy EQD_2 Benchmark in an Asian Cohort	Noor Nabila Mohamad	Malaysia
13:21-13:28	ASGO20260044	Modified cesarean radical hysterectomy for cervical cancer during pregnancy: perioperative outcomes and oncologic safety	Wang Wei	China mainland
13:28-13:35	ASGO20260649	Initial treatment and survival in regional node-negative cervical cancer aligned with FIGO 2009 IB2/IIA2 and 2018 IB3/IIA2	Jinrong Zhu·	China mainland
13:35-13:42	ASGO20260423	Dosimetric Benefits and Target-Quality Trade-offs of Proton Therapy in Cervical Cancer: A Comparison With VMAT and IMRT	Chang Liu	China mainland
13:42-13:49	ASGO20260452	Radiotherapy-guided surgical strategy for post-hysterectomy vaginal intraepithelial neoplasia secondary to cervical cancer	Lihua Zhang	China mainland
13:49-13:56	ASGO20260128	An optimized CT-guided brachytherapy workflow for cervical cancer: a retrospective study with simulation-based comparison	Xiaojing Yang	China mainland

Mini Oral Session 6

· Room: 503 December 4th 17:55-18:55 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
17:55-18:02	ASGO20260665	Cross-resistance between Prior Topoisomerase I Inhibitor Exposure and Trastuzumab Deruxtecan in Recurrent Gynecologic Cancers	Changmin Shin	Korea
18:02-18:09	ASGO20260159	Proteomics-Based Discovery and Validation of TINAGL1 and BLVRB as Predictive Biomarkers for Primary Platinum Resistance in Ovarian Cancer	Shuran Tan	China mainland
18:09-18:16	ASGO20260472	Decoding Tumour Burden and Genomic Alterations Through cfDNA in Epithelial Ovarian Cancer	Seema Singhal	India
18:16-18:23	ASGO20260021	Sequential cisplatin–navitoclax therapy exploits an evolutionary vulnerability to delay recurrence in epithelial ovarian cancer	Lin Huang	China mainland
18:23-18:30	ASGO20260366	Impact of Cisplatin Dosage in HIPEC on Survival Outcomes in the Treatment of Advanced Ovarian Cancer	Jeeyeon Kim	Korea
18:30-18:37	ASGO20260279	Analysis of the efficacy and safety of Arsenic Trioxide-based sequential combined chemotherapy in the treatment of recurrent and drug-resistant uterine malignancies: A real-world study	Yingchao Yang	China mainland
18:37-18:44	ASGO20260400	Spatial Transcriptomic Dissection of Cervical Adenocarcinoma Identifies Immune-Stromal Niches and Candidate Biomarkers	Chunlin Pan	China mainland
18:44-18:51	ASGO20260075	A shortcut from Ovarian Cancer Development to Metastasis: MYC/FASN/SEMA7A, a Promising Theragnostic Axis	Feifei Guo	China mainland

Mini Oral Session 7

· Room: 501 December 5th 17:55-18:55 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
17:55-18:02	ASGO20260575	A Simple Technique for Maintaining Suture Loop Configuration During Intracorporeal Ligation in Minimally Invasive Gynecologic Surgery	Goda Tomohiro	Japan
18:02-18:09	ASGO20260492	Manipulator-Free Technique for Single-Port Laparoscopic Hysterectomy Avoids Uterine Perforation and Reduces Blood Loss: A Propensity Score-Matched Study	Zejian Lin	China mainland
18:09-18:16	ASGO20260563	Characteristic of the first Japan-made surgical robot of 'hinotori': from our world's first gynecologic experience	Hiroaki Kobayashi	Japan
18:16-18:23	ASGO20260539	Robotic-Assisted versus Laparoscopic Surgery in Endometrial Cancer: A Comparative Analysis of Surgical and Oncological Outcomes in a Tertiary Spanish Hospital	Gregorio Lopez-Gonzalez	Spain
18:23-18:30	ASGO20260374	Indocyanine Green Sentinel Lymph Node Mapping Combined with Robot-Assisted Transvaginal Natural Orifice Transluminal Endoscopic Surgery for Endometrial Cancer Staging Surgery: A Case Series	Qian Huang	China mainland
18:30-18:37	ASGO20260564	Performance of laparoscopic photodynamic diagnosis using 5-aminolevulinic acid during interval debulking surgery for advanced ovarian cancer	Ken Yamaguchi	Japan
18:37-18:44	ASGO20260562	Preoperative Conization and Survival in Early-Stage Cervical Cancer: An Updated Meta-analysis With Trial Sequential Analysis	Pengchuang Zhang	China mainland
18:44-18:51	ASGO20260588	Hysteroscopy in Endometrial Cancer Diagnosis: a Propensity Score Matched Analysis of Its Association with Positive Peritoneal Cytology and Risk Factors	Jingying Zhang	China mainland

Mini Oral Session 8

· Room: 502 December 5th 07:00-08:00 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
07:00-07:07	ASGO20260289	PARP Inhibitor-induced Senescence of Cancer-associated Fibroblasts Drives CD8DT Cell Exhaustion and Immunotherapy Resistance in Ovarian Cancer	Chenmian Liu	China mainland
07:07-07:14	ASGO20260347	EZH2 Inhibition Enhances Checkpoint Inhibitor Blockade Response in Ovarian Cancer	Yuhan Cai	China mainland
07:14-07:21	ASGO20260711	Tumor–stroma proportion and survival in advanced ovarian cancer in the poly(ADP-ribose) polymerase inhibitor maintenance era	Tao Wu	China mainland
07:21-07:28	ASGO20260574	Development of Myeloid Neoplasms After Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Patients with Ovarian Cancer	Kazuki Yokota	Japan
07:28-07:35	ASGO20260274	Photothermal-responsive hydrogel microcapsules with programmable drug release for enhanced ovarian cancer therapy	Zhengwei Sun	China mainland
07:35-07:42	ASGO20260013	Targeting SIK2 initiates CD8+ T-cell immunity to enhance immunotherapy efficacy in ovarian cancer	Fang Wang	China mainland
07:42-07:49	ASGO20260157	Combined Cyclin-Dependent Kinase 7 and 9 Inhibition Induces Functional Homologous Recombination Deficiency and Sensitizes Ovarian Cancer to Poly(ADP-Ribose) Polymerase Inhibition	Jingxin Lv	China mainland
07:49-07:56	ASGO20260596	Efficacy of Combination Therapy with PARP Inhibitors and Immune Checkpoint Inhibitors in Recurrent Ovarian Cancer: a Systematic Review and Meta-Analysis	Yahya Nurlianto	Indonesia

Mini Oral Session 9

· Room: 502 December 5th 16:50-17:50 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
16:50-16:57	ASGO20260571	Ordinal-Coordinate Mixture-of-Experts Improves Foundation-Model Prediction of Homologous-Recombination Deficiency from H&E in Ovarian Cancer	Jingxin Guo	China mainland
16:57-17:04	ASGO20260485	Censoring-Aware Clinical-Token Transformer for Overall Survival Prediction in Cervical Cancer Using SEER: Temporal Validation Against Statistical, Machine-Learning, and Deep-Learning Models with Cross-Model SHAP Interpretation	Runhua Li	China mainland
17:04-17:11	ASGO20260616	Second-Generation Molecular Refinement of No Specific Molecular Profile Endometrial Cancer: A Multi-Omics Classification With a Clinic-Ready Panel	Huan Yi	China mainland
17:11-17:18	ASGO20260658	Prediction model for bladder dysfunction after nerve-sparing radical hysterectomy in cervical cancer patients using machine learning	Kamonrat Monthatip	Thailand
17:18-17:25	ASGO20260630	Evaluating the Readability and Quality of AI-Generated Ovarian Cancer Education Materials: A Comparative Analysis of Five Large Language Models	Tian Hua	China mainland
17:25-17:32	ASGO20260470	Patient-Derived Organoids for Personalized Disease Modelling and Therapeutic Strategy Screening in Gastric-Type Endocervical Adenocarcinoma, the Most Common and Aggressive HPV-Independent Cervical Cancer	Ming Du	China mainland
17:32-17:39	ASGO20260499	Analytical performance of POPLAR, a next-generation sequencing-based software as a medical device for molecular classification of endometrial carcinoma	Hiroshi Asano	Japan
17:39-17:46	ASGO20260352	Real-World Evaluation of Sentinel Lymph Node Strategies in Endometrial Cancer Across Risk Strata	Zhengmao Zhang	China mainland

Mini Oral Session 10

· Room: 502 December 5th 17:55-18:55 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
17:55-18:02	ASGO20260097	NHE7 Promotes Progestin Resistance in Endometrial Tumor by Regulating Intracellular pH and sAC/cAMP/MAPK Signaling	Shizhou Yang	China mainland
18:02-18:09	ASGO20260627	Targeting Intratumoral Pseudomonas aeruginosa Disrupts Tunneling Nanotube-Mediated Mitochondrial Transfer and Restores Carboplatin Sensitivity in Endometrial Cancer	Chao Meng	China mainland
18:09-18:16	ASGO20260003	A Multicellular Pro-invasive Ecosystem Drives Lymphovascular Space Invasion in Endometrioid Endometrial Carcinoma	Wendi Guo	China mainland
18:16-18:23	ASGO20260288	AC1Q3QWB Enhances Progesterone Sensitivity in Endometrial Cancer by Selectively Targeting the PRC2-Dependent Function of EZH2	Jiale Liu	China mainland
18:23-18:30	ASGO20260070	Fertility-Sparing Therapy with Immune Checkpoint Inhibitors in POLEmut Endometrial Cancer	Weiwei Shan	China mainland
18:30-18:37	ASGO20260446	Pan cancer spatial heterogeneity of immune cell infiltration predicts poor clinical outcomes and is reversible by PI3Kα inhibition	Zhe Hu	China mainland
18:37-18:44	ASGO20260002	ERRγ-TRAP1 Axis Stabilizes Mutant p53 to Drive Endometrial Cancer Invasion	Yue Wang	China mainland
18:44-18:51	ASGO20260639	Single-Cell Transcriptomic Profiling Reveals WNT/PI3K Dysregulation and JAK–STAT/MAPK Activation across Differentiation States in Endometrioid Endometrial Cancer	Putri Deva Karimah	Indonesia

Mini Oral Session 11

· Room: 503 December 5th 16:50-17:50 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
16:50-16:57	ASGO20260090	Early Emotional Awareness Difficulties and Somatic Symptom Burden after Bilateral Oophorectomy for Gynecologic Tumors	Xin Zhang	China mainland
16:57-17:04	ASGO20260360	Clinicopathological Features and Prognostic Analysis of Synchronous Primary Colorectal and Endometrial Cancers	Xuemin Hu	China mainland
17:04-17:11	ASGO20260014	Perioperative Immunonutrition Improves Clinical Outcomes and Preserves Muscle Mass in Gynaecological Cancer: Evidence from an ERAS-Based Mixed-Methods Study	Chiou Yi Ho	Malaysia
17:11-17:18	ASGO20260241	Competing Risk Analysis of Cardiovascular Death and Socioeconomic Determinants in Elderly Patients with Endometrioid Endometrial Cancer: A SEER-Based Study	Jing Zhang	China mainland
17:18-17:25	ASGO20260683	Refining Surgical Decision-Making in Atypical Endometrial Hyperplasia: A Dual Nomogram for Preoperative Risk Stratification of Occult Malignancy	Qiaoying Lv	China mainland
17:25-17:32	ASGO20260484	Global burden, development inequalities, and projections of cervical cancer to 2050: a population-based analysis of GLOBOCAN 2024 estimates in 186 countries and territories	Runhua Li	China mainland
17:32-17:39	ASGO20260123	Predictive Value of a Multi-lipid Panel Score for Complete Remission in Atypical Endometrial Hyperplasia and Early Endometrial Cancer Receiving Fertility-Sparing Therapy	Xinyi Bi	China mainland
17:39-17:46	ASGO20260007	Machine learning-based model for Prognostic Risk Stratification in Cervical Clear Cell Adenocarcinoma (CLEARIS): A global modelling study	Binhua Dong	China mainland
17:46-17:53	ASGO20260612	A Random Survival Forest-Derived Risk Stratification Model and Simplified Clinical Score for Prognosis and Treatment Optimization in Vulvar Squamous Cell Carcinoma	Xingyun Xie	China mainland

Mini Oral Session 12

· Room: 503 December 5th 17:55-18:55 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
17:55-18:02	ASGO20260696	Risk Stratification of Cervical Precancerous Lesions Based on Combined Detection of Cytology, HR-HPV DNA and p16/Ki-67 Dual Staining	Duancheng Tian	China mainland
18:02-18:09	ASGO20260578	Circulating miRNA Signatures in Cancer-Free BRCA1/2 Pathogenic Variant Carriers Reveal Genetically Supported Links to Ovarian Cancer Susceptibility	Xueping Zhu	China mainland
18:09-18:16	ASGO20260136	Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion Cytologic Interpretation and Histologic Outcomes: A Five-Year Study at a Tertiary Care Center	Thanawit Poolsin	Thailand
18:16-18:23	ASGO20260458	Traction-Guided Incremental Excision During LEEP: Technique and Eight-Year Outcomes	Taehun Kim	Korea
18:23-18:30	ASGO20260189	Progress Toward Cervical Cancer Elimination in North Sumatra, Indonesia: A Province-Wide Assessment of Screening Coverage, Health System Capacity, and HPV DNA Implementation	FELIX KHOSASI	Indonesia
18:30-18:37	ASGO20260384	Addressing over-referral in cervical cancer screening: DNA methylation triage with PAX1/JAM3	ShengQian Wang	China mainland
18:37-18:44	ASGO20260052	Validation of Dual Gene Methylation in Cervical Scrapings as a Triage Tool for Endometrial Cancer in Women with Abnormal Uterine Bleeding	Zhang Shen	China mainland
18:44-18:51	ASGO20260054	Patient Self-Sampling for CDO1/CELF4 Methylation Testing as a Molecular Triage Strategy for Endometrial Cancer in Northwest China	Feixue Xu	China mainland

Mini Oral Session 13

· Room: 503 December 6th 07:25-08:25 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
07:25-07:32	ASGO20260253	CVRSe Induces FDX1-Independent Cuproptosis: Implications for Cisplatin-Resistant Cervical Cancer	Hejing Liu	China mainland
07:32-07:39	ASGO20260293	PFKL Lysine 677 Lactylation Couples Glycolytic Flux to ERK Signaling Through a Self-reinforcing Redox-active Loop in Cervical Cancer	Fanghua Chen	China mainland
07:39-07:46	ASGO20260252	GGCT mediates BZW2/GSK3β/β-catenin signaling to drive cervical cancer progression	Qingfeng Zhou	China mainland
07:46-07:53	ASGO20260704	Tumor-derived extracellular vesicles derived HPV E7 suppress STING signaling and CD8D T-cell cytotoxicity in cervical cancer	Yue Zhang	China mainland
07:53-08:00	ASGO20260193	YTHDF3 regulates PD-L1 expression to promote immune evasion in cervical cancer	Liqing Miao	China mainland
08:00-08:07	ASGO20260195	MIF affects the Senescence of Cervical Cancer cells through the Tryptophan Metabolic Pathway	He Zhu	China mainland
08:07-08:14	ASGO20260716	Maggot Extract Inhibits Cervical Cancer Progression by Inducing G2/M Cell Cycle Arrest	Yue Sun	China mainland
08:14-08:21	ASGO20260410	Early Viral Genome Dissemination and Integration-Driven CXCL8/ARNT2 Activation Along the Primary Tumor–Lymph Node Axis in Cervical Cancer	Qian Zheng	China mainland

Mini Oral Session 14

· Room: 502 December 6th 07:25-08:25 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
07:25-07:32	ASGO20260422	Pembrolizumab vs Placebo + Paclitaxel ± Bevacizumab for Platinum-Resistant Recurrent Ovarian Cancer: Post Hoc Analysis in the East Asia Subgroup of the ENGOT-ov65/KEYNOTE-B96 Study	Jae-Weon Kim	Korea
07:32-07:39	ASGO20260676	First-line niraparib maintenance therapy in BRCA wild-type, low-risk advanced ovarian cancer: The POLO trial	Se Ik Kim	Korea
07:39-07:46	ASGO20260290	BRCA1/2 Mutation Characteristics and First-Line PARP Inhibitor Maintenance Therapy Efficacy in Advanced Ovarian Cancer: A Multicenter Real-World Study	Qingxiu Jiang	China mainland
07:46-07:53	ASGO20260448	Surufatinib Combined with Toripalimab in Patients with Recurrent Ovarian Clear Cell Carcinoma: Updated Results from A Prospective Single Center, Single-Arm Phase II Clinical Trial	Wenbin Shen	China mainland
07:53-08:00	ASGO20260598	Disitamab Vedotin–Based Therapy in HER2-Expressing Platinum-Sensitive Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer: DIVERSITY Study	Tong Shu	China mainland
08:00-08:07	ASGO20260679	Final survival outcomes of the OPEB-01/APGOT-OV4 trial and identify clinical and molecular determinants of durable benefit	Se Ik Kim	Korea
08:07-08:14	ASGO20260667	QLS5132, a novel claudin 6-targeting antibody-drug conjugate, in patients with platinum- resistant ovarian cancer: Updated results from a phase 1 trial	Zhuyan Shao	China mainland
08:14-08:21	ASGO20260445	Final Outcomes of Dalpiciclib and Nonsteroidal Aromatase Inhibitors (NSAIs) in Estrogen Receptor-Positive (ER+) Recurrent/Metastatic (R/M) Ovarian Cancer and Uterine Neoplasms.	Wei Jiang	China mainland

Mini Oral Session 15

· Room: 502 December 6th 13:00-14:00 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
13:00-13:07	ASGO20260141	BRCA2 Non-Ovarian Cancer Cluster Region Mutations and Prognosis of FirstLine PARP Inhibitor Maintenance Therapy: A Multicenter Retrospective Nomogram Study in Chinese Population	Xi Chen	China mainland
13:07-13:14	ASGO20260565	BRCA1/2 Synonymous Variants are Associated with Favorable Outcomes to PARP Inhibitor Maintenance in Ovarian Cancer	Dongdong Ye	China mainland
13:14-13:21	ASGO20260491	Shared and Site-Specific Molecular Features of Cervical, Endometrial, and Ovarian Clear Cell Carcinomas	Zejian Lin	China mainland
13:21-13:28	ASGO20260435	Integrated Deconvolution of Plasma Cell-Free RNA Reveals Immune and Tissue-Origin Signatures Linked to Clinical Parameters in Gynecological Cancers	Misi He	China mainland
13:28-13:35	ASGO20260053	Non-invasive Prediction of BRCA Mutation Status in Ovarian Cancer Using Whole-body Tumor Burden Deep Learning: A Novel Pathway Towards Precision Medicine and Accessible Genetic Testing	Xinru Li	China mainland
13:35-13:42	ASGO20260378	A Non-Invasive Three-Gene cfDNA Methylation Panel for the Early Detection of Epithelial Ovarian Cancer: Development and Independent Validation	Tong Shu	China mainland
13:42-13:49	ASGO20260137	FDR-controlled serum metabolic fingerprints encode ovarian cancer diagnosis	Wanshan Liu	China mainland
13:49-13:56	ASGO20260163	Development and Validation of a Screening Model for Ovarian Cancer Based on Exhaled Breath Volatile Organic Compounds	Mei Liu	China mainland

Mini Oral Session 16

· Room: 504 December 6th 07:25-08:25 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
07:25-07:32	ASGO20260399	“Less Is More”: Comparable Efficacy and Favorable Safety of a Reduced-Dose PEB Regimen in Malignant Ovarian Germ Cell Tumors	Yuan Feng	China mainland
07:32-07:39	ASGO20260332	Early Stage Ovarian Immature Teratoma: Surveillance or Chemotherapy After Surgery? A prospective, real-world study from Chinese national center of rare disease.	Xinyue Zhang	China mainland
07:39-07:46	ASGO20260201	Full Clinical Spectrum of Wandering Leiomyoma and Coincidental Pulmonary Adenomyoma: From Intracardiac and Pulmonary Debulking to Definitive Hysterectomy and Bilateral Salpingo-Oophorectomy	Fauziah Rathi	Indonesia
07:46-07:53	ASGO20260331	Non-Dysgerminoma Malignant Ovarian Germ Cell Tumors in 46,XY Pure Gonadal Dysgenesis (Swyer Syndrome): Clinical Features, Prognosis, and Long-term Management	Xinyue Zhang	China mainland
07:53-08:00	ASGO20260455	Methylation Landscape of Malignant Ovarian Germ Cell Tumors	Xinyang Jin	China mainland
08:00-08:07	ASGO20260135	Epidemiological Characteristics and Economic Burden of Malignant Ovarian Germ Cell Tumors Among Children, Adolescents and Young Adults in China	Jing Zheng	China mainland
08:07-08:14	ASGO20260675	Oncological Outcomes of Fertility-Sparing Surgery in Patients with Borderline Ovarian Tumors	Guo Zheng	China mainland

Mini Oral Session 17

· Room: 504 December 6th 13:00-14:00 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
13:00-13:07	ASGO20260603	Single-cell screening of PARP inhibitor-induced malignant epithelial programs identifies an immune-visible prognostic axis in high-grade serous ovarian cancer	He Zhang	China mainland
13:07-13:14	ASGO20260091	The Study of Malic Enzyme 1 Driving the Progression of Epithelial Ovarian Cancer and Platinum Resistance through Metabolic Reprogramming	Jiahui Wei	China mainland
13:14-13:21	ASGO20260646	Characterization and clinical relevance of an epithelial-retained plastic malignant-cell state in ovarian clear cell carcinoma	Tianyue Zhai	Japan
13:21-13:28	ASGO20260585	Neutrophil Extracellular Traps Restrict T Cell Infiltration by Degrading C-X-C motif chemokine ligand 11 in High Grade Serous Ovarian Cancer	Kohei Tamura	Japan
13:28-13:35	ASGO20260301	Targeting DLST lipoylation with pyridoxal triggers therapeutic cuproptosis in ovarian cancer	Ruonan Li	China mainland
13:35-13:42	ASGO20260342	Advances in CAF-Targeting Strategies: Translational Challenges and Future Perspectives for Refractory Peritoneal Metastasis in Ovarian Cancer	Yanping Jiang	China mainland
13:42-13:49	ASGO20260414	Plasma Cell-Free RNA Reveals Tumor-Specific Metabolic Remodeling in Gynecological Malignancies with Tissue-Plasma Transcriptional Concordance Validation	Misi He	China mainland
13:49-13:56	ASGO20260604	A multi-omics and pharmacogenomic prioritization of a FANCD2/USP1-associated DNA repair program in ovarian cancer treatment response	He Zhang	China mainland
13:56-14:03	ASGO20260653	Distinct geospatial immune contextures of primary and relapsed ovarian clear cell carcinoma	Guolun Zhu	China mainland